Enlivex Therapeutics Ltd's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 190 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend up.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Enlivex Therapeutics Ltd is 5.38, ranking 371 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Key Metrics
The current valuation score of Enlivex Therapeutics Ltd is 7.20, ranking 148 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is 0.04, which is 14.43% below the recent high of 0.04 and 8225.77% above the recent low of -3.15.
The current earnings forecast score of Enlivex Therapeutics Ltd is 7.00, ranking 312 out of 391 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 7.00 and a low of 7.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Enlivex Therapeutics Ltd is 5.62, ranking 309 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.24 and the support level at 0.94, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Enlivex Therapeutics Ltd is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 13.33%, representing a quarter-over-quarter decrease of 3.50%. The largest institutional shareholder is Catherine Wood, holding a total of 628.31K shares, representing 0.26% of shares outstanding, with 1.00% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Enlivex Therapeutics Ltd. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
